Suppr超能文献

PLCE1 基因突变分析在激素耐药性肾病综合征中的作用。

Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome.

机构信息

INSERM U983, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, Paris, France.

出版信息

J Med Genet. 2010 Jul;47(7):445-52. doi: 10.1136/jmg.2009.076166.

Abstract

BACKGROUND

Mutations in the PLCE1 gene encoding phospholipase C epsilon 1 (PLCepsilon1) have been recently described in patients with early onset nephrotic syndrome (NS) and diffuse mesangial sclerosis (DMS). In addition, two cases of PLCE1 mutations associated with focal segmental glomerulosclerosis (FSGS) and later NS onset have been reported.

METHOD

In order to better assess the spectrum of phenotypes associated with PLCE1 mutations, mutational analysis was performed in a worldwide cohort of 139 patients (95 familial cases belonging to 68 families and 44 sporadic cases) with steroid resistant NS presenting at a median age of 23.0 months (range 0-373).

RESULTS

Homozygous or compound heterozygous mutations were identified in 33% (8/24) of DMS cases. PLCE1 mutations were found in 8% (6/78) of FSGS cases without NPHS2 mutations. Nine were novel mutations. No clear genotype-phenotype correlation was observed, with either truncating or missense mutations detected in both DMS and FSGS, and leading to a similar renal evolution. Surprisingly, three unaffected and unrelated individuals were also found to carry the homozygous mutations identified in their respective families.

CONCLUSION

PLCE1 is a major gene of DMS and is mutated in a non-negligible proportion of FSGS cases without NPHS2 mutations. Although additional variants in 19 candidate genes (16 other PLC genes, BRAF,IQGAP1 and NPHS1) were not identified, it is speculated that other modifier genes or environmental factors may play a role in the renal phenotype variability observed in individuals bearing PLCE1 mutations. This observation needs to be considered in the genetic counselling offered to patients.

摘要

背景

最近在早发性肾病综合征(NS)和弥漫性系膜硬化(DMS)患者中发现了编码磷脂酶 C ɛ1(PLCɛ1)的 PLCE1 基因突变。此外,还报道了两例与局灶节段性肾小球硬化(FSGS)和后来的 NS 发病相关的 PLCE1 突变病例。

方法

为了更好地评估与 PLCE1 突变相关的表型谱,对来自 139 名患者(95 例家族性病例属于 68 个家族,44 例散发性病例)的全球队列进行了突变分析,这些患者患有激素耐药性 NS,中位年龄为 23.0 个月(范围 0-373)。

结果

在 33%(8/24)的 DMS 病例中发现了纯合子或复合杂合子突变。在没有 NPHS2 突变的 FSGS 病例中发现了 8%(6/78)的 PLCE1 突变。其中 9 个是新的突变。没有观察到明显的基因型-表型相关性,在 DMS 和 FSGS 中均检测到截断或错义突变,并导致相似的肾脏演变。令人惊讶的是,还发现了三个未受影响且无亲缘关系的个体携带了各自家族中发现的纯合突变。

结论

PLCE1 是 DMS 的主要基因,在没有 NPHS2 突变的非小比例 FSGS 病例中发生突变。虽然未发现 19 个候选基因(其他 16 个 PLC 基因、BRAF、IQGAP1 和 NPHS1)的其他变体,但推测其他修饰基因或环境因素可能在携带 PLCE1 突变的个体中观察到的肾脏表型变异性中起作用。这一观察结果需要在向患者提供遗传咨询时加以考虑。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验